Abvc Biopharma (ABVC) Current Leases (2019 - 2026)
Abvc Biopharma's (ABVC) quarterly Current Leases came in at $332252.0 in Q1 2026, down 9.34% YoY from $366475.0 in Q1 2025, and up 4.63% on a QoQ basis from $317557.0 in Q4 2025.
Abvc Biopharma (ABVC) Current Leases (2019 - 2026) Analysis & Trends
Abvc Biopharma (ABVC) has 8 years of Current Leases data on file, last reported at $332252.0 in Q1 2026.
- Quarterly Current Leases fell 9.34% year-over-year to $332252.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $332252.0 (down 9.34% YoY) and the FY2025 annual result came in at $317557.0, down 21.32% from the prior year.
- Current Leases improved to $332252.0 in Q1 2026, from $317557.0 in the prior quarter.
- In the past five years, Current Leases ranged from a high of $403581.0 in Q4 2024 to a low of $199335.0 in Q3 2025.
- A 5-year average of $355271.0 and a median of $366475.0 in 2025 frame the typical range for Current Leases.
- Annual changes were most pronounced in 2023 — Current Leases advanced 11.48% — and 2025, when it sank 45.46%.
- Tracing ABVC's Current Leases over 5 years: stood at $369314.0 in 2022, then gained by 8.8% to $401826.0 in 2023, then rose by 0.44% to $403581.0 in 2024, then fell by 21.32% to $317557.0 in 2025, then gained by 4.63% to $332252.0 in 2026.
- The last three Current Leases figures came in at $332252.0 (Q1 2026), $317557.0 (Q4 2025), and $199335.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 720.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 21.95 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 45.93 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Abvc Biopharma | 23.19 Mn | 23.19 Mn | - | 358,107.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 358,107.00 |
| Mar 31, 2026 | 332,252.00 |
| Dec 31, 2025 | 317,557.00 |
| Sep 30, 2025 | 199,335.00 |
| Jun 30, 2025 | 282,192.00 |
| Mar 31, 2025 | 366,475.00 |
| Dec 31, 2024 | 403,581.00 |
| Sep 30, 2024 | 365,458.00 |
| Jun 30, 2024 | 378,199.00 |
| Mar 31, 2024 | 389,870.00 |
| Dec 31, 2023 | 401,826.00 |
| Sep 30, 2023 | 392,666.00 |
| Jun 30, 2023 | 390,505.00 |
| Mar 31, 2023 | 387,333.00 |
| Dec 31, 2022 | 369,314.00 |
| Sep 30, 2022 | 363,752.00 |
| Jun 30, 2022 | 350,284.00 |
| Mar 31, 2022 | 349,008.00 |
| Dec 31, 2021 | 347,100.00 |
| Sep 30, 2021 | 342,131.00 |